BR0307868A - Estratégia para imunoterapia retroviral - Google Patents

Estratégia para imunoterapia retroviral

Info

Publication number
BR0307868A
BR0307868A BR0307868-0A BR0307868A BR0307868A BR 0307868 A BR0307868 A BR 0307868A BR 0307868 A BR0307868 A BR 0307868A BR 0307868 A BR0307868 A BR 0307868A
Authority
BR
Brazil
Prior art keywords
cells
retroviral
mammal
strategy
produced
Prior art date
Application number
BR0307868-0A
Other languages
English (en)
Inventor
Martin Leonard Ashdown
Original Assignee
Immunaid Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunaid Pty Ltd filed Critical Immunaid Pty Ltd
Publication of BR0307868A publication Critical patent/BR0307868A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ESTRATéGIA PARA IMUNOTERAPIA RETROVIRAL". O presente inventor notou que pelo menos duas populações de células imunes são produzidas em resposta ao retrovírus que infectam mamíferos. Mais particularmente, o sistema imune de um mamífero infectado com um retrovírus é capaz de montar uma resposta imune contra o vírus através de um grupo de células aqui geralmente referidas como "células efetoras", entretanto, uma segunda população de células é também produzida a qual regula as "células efetoras", aqui geralmente referida como "células reguladoras" ou células supressoras, limitando a capacidade do mamífero de controlar efetivamente ou erradicar a infecção retroviral. Conseq³entemente, a presente invenção utiliza estas observações para fornecer métodos para tratar um mamífero com uma infecção retroviral. Além disso, o presente inventor descobriu que os marcadores inflamatórios de fase aguda podem ser usados para detectar e monitorar uma resposta de "célula efetoral, aos antígenos retrovirais.
BR0307868-0A 2002-02-20 2003-02-18 Estratégia para imunoterapia retroviral BR0307868A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS0650A AUPS065002A0 (en) 2002-02-20 2002-02-20 Strategy for retroviral immunotherapy
PCT/AU2003/000207 WO2003070270A1 (en) 2002-02-20 2003-02-18 Strategy for retroviral immunotherapy

Publications (1)

Publication Number Publication Date
BR0307868A true BR0307868A (pt) 2004-12-07

Family

ID=3834249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307868-0A BR0307868A (pt) 2002-02-20 2003-02-18 Estratégia para imunoterapia retroviral

Country Status (11)

Country Link
EP (1) EP1482971B1 (pt)
JP (1) JP2005526729A (pt)
CN (2) CN101354397A (pt)
AU (1) AUPS065002A0 (pt)
BR (1) BR0307868A (pt)
CA (1) CA2476956A1 (pt)
DK (1) DK1482971T3 (pt)
ES (1) ES2441742T3 (pt)
PT (1) PT1482971E (pt)
WO (1) WO2003070270A1 (pt)
ZA (1) ZA200407143B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283322B2 (en) * 2003-10-24 2010-09-16 Biotempus Pty Ltd Method of therapy
US20070202119A1 (en) * 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
EP1805510B1 (en) * 2004-09-08 2012-02-22 Immunaid Pty Ltd Therapeutic strategy for treating autoimmune and degenerative diseases
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
CN104013959A (zh) * 2014-05-21 2014-09-03 郭和友 逆转录抑制剂和免疫抗体细胞三联合疗法
AU2018375738A1 (en) * 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
CN115029429B (zh) * 2022-06-02 2022-11-22 中国人民解放军总医院第五医学中心 炎症相关蛋白联合在预测art治疗敏感性中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
AU641375B2 (en) 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
AUPQ948800A0 (en) * 2000-08-18 2000-09-07 Immunaid Pty Ltd A vaccine strategy
US20070202119A1 (en) * 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy

Also Published As

Publication number Publication date
DK1482971T3 (da) 2014-01-13
ZA200407143B (en) 2005-09-29
CN101354397A (zh) 2009-01-28
WO2003070270A1 (en) 2003-08-28
CN1646156A (zh) 2005-07-27
CA2476956A1 (en) 2003-08-28
ES2441742T3 (es) 2014-02-06
EP1482971A4 (en) 2008-09-03
PT1482971E (pt) 2013-12-24
EP1482971B1 (en) 2013-10-09
AUPS065002A0 (en) 2002-03-14
JP2005526729A (ja) 2005-09-08
EP1482971A1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
Chang et al. Proton transport by gastric membrane vesicles
Bektaş et al. Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton
BR0203650A (pt) Estentor de auto-articulação
BR0309809A (pt) indução de toleráncia imunológica especìfica quanto ao antìgeno
BR0207733A (pt) Processo para a regulação de um processo termodinâmico, especialmente de um processo de combustão
BR112014016643A8 (pt) estruturas fibrosas contendo ativo com múltiplas regiões tendo densidades diferentes
AR014743A1 (es) Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
BR0012768A (pt) Sistema de células de combustìvel
BR9910359A (pt) Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso
BR112021022757A2 (pt) Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo
BRPI0820177B8 (pt) métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
BR112015017797A2 (pt) celobio-hidrolase termoestável
BR0307868A (pt) Estratégia para imunoterapia retroviral
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
BR0003072A (pt) Fechadura de cilindro dotada de meios de orientação magneticamente operados
BR112013017445A2 (pt) métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
BR0113354A (pt) Imunoterapia retroviral
BR0111630A (pt) Espiral para inseto
BR0308810A (pt) Células hospedeiras tendo propriedades melhoradas de sobrevivência celular e métodos para gerar tais células
BR112023002724A2 (pt) Neoantígenos ras e seus usos
Phillips et al. 2, 3-Butanedione 2-monoxime (BDM) induces calcium release from canine cardiac sarcoplasmic reticulum
BR112022000847A2 (pt) Método para inativação viral
von Essen et al. PKC‐θ exists in an oxidized inactive form in naive human T cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.